

PRIMARY RESEARCH

Open Access



microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer

Shanshan Chen¹, Ping Li¹, Rui Yang¹, Ruirui Cheng¹, Furui Zhang¹, Yuanyuan Wang², Xiaonan Chen², Qianqian Sun², Wenqiao Zang², Yuwen Du², Guoqiang Zhao^{2*} and Guojun Zhang^{1*}

Abstract

Background: Non-small cell lung cancer (NSCLC) is the largest histological subgroup of lung cancer and has increased in prevalence in China over the past 5 years. The 5-year survival rate has remained at 15–20 %, with a median survival of 8–12 months. The tumorigenesis and progression of NSCLC is orchestrated by numerous oncogene and anti-oncogene mutations and insights into microRNA function have increased our understanding of the process. Here, we investigated the effects of miR-30b on NSCLC cell invasion and migration and explored the underlying molecular mechanisms involved.

Methods: Quantitative reverse transcription PCR, wound healing assay, trans-well assays, western blotting and dual luciferase assays were performed to investigate the molecular mechanisms of miR-30b in NSCLC cells.

Results: MiR-30b was down-regulated and Cthrc1 up-regulated in NSCLC tissues. Both were associated with tumor differentiation, TNM stage and lymph node metastases. Up-regulation of miR-30b restricted A549 and Calu-3 cell invasion and migration. Additionally, the expression of Cthrc1, matrix metalloproteinase-9 and matrix metalloproteinase-2 was reduced, while metalloproteinase inhibitor-1 expression increased. Bioinformatics analysis identified Cthrc1 as a target of miR-30b and western blotting and luciferase reporter assays confirmed that miR-30b regulates Cthrc1 by directly binding to its 3'UTR. Transfection of Cthrc1 without the 3'UTR restored the miR-30b inhibiting cell invasion. Up-regulation of miR-30b or down-regulation of Cthrc1 had potential significance in the invasion and metastasis of NSCLC.

Conclusions: MiR-30b was down-regulated and Cthrc1 up-regulated in NSCLC tissues. Both of them were related to tumor differentiation, TNM stage and lymph node metastases. MiR-30b affected NSCLC cells invasion and migration by regulating Cthrc1.

Keywords: Non-small cell lung cancer, miR-30b, Cthrc1, Invasion, Migration

Background

Lung cancer is the most common cause of cancer-associated deaths worldwide [1]. Non-small cell lung cancer

(NSCLC) is the largest histological subgroup, accounting for 80–85 % of all lung cancers [2]. Although substantial progress has been made in the surgical treatment, radiotherapy and chemotherapy of NSCLC [3–6], the 5-year survival rate has remained at 15–20 %, with median survival of 8–12 months [7]. The tumorigenesis and progression of NSCLC is a complex process influenced by multiple genetic factors, therefore early diagnosis and treatment is important. Preventing the tumorigenesis

*Correspondence: zhaogq@zzu.edu.cn; gjzhangzsu@126.com

¹ Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

² Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China

Full list of author information is available at the end of the article

and progression of NSCLC at the molecular level is the key to an effective therapeutic strategy.

Insights into the oncogenic and tumor-suppressor functions of microRNAs (miRNAs) have contributed to our understanding of NSCLC tumorigenesis and progression. miRNAs are small noncoding RNA molecules that regulate the expression of at least 30 % of all protein-coding genes, influencing a variety of biological functions such as cell proliferation and survival, DNA repair and immune response [8–10]. Assorted miRNAs have been confirmed to play important roles in NSCLC. For example, miR-96 and miR-21 are significantly up-regulated in NSCLC tissues and regulate target gene expression to influence NSCLC cell migration and invasion [11, 12]. The tumor suppressor's miR-495, miR-486-5p and miR-193a-3p/5p are all down-regulated in NSCLC tissues, contributing to the tumorigenesis and progression of the disease [13–15].

MiR-30b is a member of the miR-30 family, which plays an important regulatory role in the development of several cancers including breast cancer [16], malignant peripheral nerve sheath tumors [17], glioma [18] and lung cancer [19]. Collagen triple helix repeat containing 1 (Cthrc1) has also been associated with the development of certain cancers, including lung cancer [20–24], therefore we decided to explore a possible interaction between miR-30b and Cthrc1 and the potential significance in the invasion and metastasis of NSCLC.

In our study, we detected miR-30b and Cthrc1 expression levels in NSCLC tissues, and observed alterations in invasion, migration and expression of some metastasis associated proteins by increasing miR-30b expression in NSCLC cell lines. We next performed dual luciferase assay system and western blotting analysis on the basis of bioinformatics analysis using TargetScan and miRanda to investigate whether miR-30b regulated the expression of Cthrc1 via binding to its 3'UTR. Furthermore, co-transfection of miR-30b and pcDNA3.1-Cthrc1 can help to explore whether the effect of miR-30b can be partially restored by Cthrc1 re-expression.

Results

MiR-30b is down-regulated in NSCLC tissues

Expression of miR-30b was evaluated in 63 NSCLC and adjacent normal tissues. We found that miR-30b expression was significantly down-regulated in NSCLC tissues compared to adjacent normal tissues ($P < 0.05$, Fig. 1a). Further analysis revealed that miR-30b expression in NSCLC tissues was associated with differentiation, TNM stage and lymph node metastases ($P < 0.05$; Table 1; Fig. 1b–d). No significant differences were observed between miR-30b expression and gender, age or pathological type ($P > 0.05$; Table 1).

Cthrc1 mRNA is up-regulated in NSCLC tissues

Expression of Cthrc1 mRNA was also evaluated in 63 NSCLC and adjacent normal tissues. Cthrc1 mRNA expression was significantly up-regulated in NSCLC tissues ($P < 0.05$, Fig. 2a) and was also associated with differentiation, TNM stage and lymph node metastases ($P < 0.05$, Table 1; Fig. 2b–d). No significant differences were observed between Cthrc1 mRNA expression and gender, age or pathological type ($P > 0.05$; Table 1). Pearson correlation analysis indicated that the expression of miR-30b and Cthrc1 mRNA were inversely correlated ($R^2 = 0.734$, Fig. 2e).

MiR-30b inhibits the migration and invasion of NSCLC cells

To investigate the effect of miR-30b on the migration and invasion of NSCLC cells, miR-30b mimic or a scrambled miR-30b negative control were transfected into A549 and Calu-3 cells respectively. qRT-PCR results showed miR-30b expression was significantly increased in the miR-30b group compared with the NHBE, Scramble and Blank groups ($P < 0.05$, Fig. 3a). The wound healing assay and trans-well arrays for migration ability revealed that the migration ability of A549 and Calu-3 cells in the miR-30b group was lower at 24 h post-wounding compared with both Scramble and Blank groups ($P < 0.05$, Fig. 3b, c). The cell invasion assay revealed a significant reduction in the average number of cells penetrating the trans-well membrane and matrigel in the miR-30b group ($P < 0.05$, Fig. 3d), while cells in the Scramble and Blank groups were not affected ($P > 0.05$). The expression of Cthrc1 and other invasion-related proteins such as TIMP-1, MMP-2 and MMP-9 were analyzed by western blotting. Cthrc1, MMP-2 and MMP-9 expression was reduced but TIMP-1 expression increased following transfection with miR-30b in A549 and Calu-3 cells ($P < 0.05$, Fig. 3e, f). Taken together, these findings suggest that miR-30b plays an important role in cell migration and invasion.

MiR-30b down-regulates the expression of Cthrc1 via binding to their 3'UTR

Bioinformatics analysis by TargetScan and miRanda revealed a predicted binding site for miR-30b in the 3'UTR of Cthrc1 (Fig. 4a). Furthermore, Cthrc1 expression decreased in A549 and Calu-3 cells following transfection with miR-30b mimics (Fig. 4b, c). To confirm whether Cthrc1 is a direct target of miR-30b, we performed a dual-luciferase reporter assay using luciferase-reporter vectors containing either the wild-type or the mutant 3'UTR of Cthrc1. While co-transfection with miR-30b mimics significantly decreased the luciferase activity of the reporter containing wild-type 3'UTR, it did not suppress that of the mutant-type reporter in A549 and Calu-3 cells ($P < 0.05$, Fig. 4d, e). These findings




Fig. 1 Expressions of miR-30b in paired NSCLC and adjacent normal tissues. **a** Relative expression levels of miR-30b in paired NSCLC and adjacent normal tissues. There is a statistically significant difference ($P < 0.05$). **b** On the basis of differentiation, NSCLC tissues were divided into two groups (Well and Moderate & Poor). The down-regulation of miR-30b was notably in Moderate & Poor group ($P < 0.05$). **c** In TNM stage of tumor tissues, the expression of miR-30b was successively declined ($P < 0.05$). **d** On the basis of lymph node metastases, the expression of miR-30b was significantly lower in N0 group than N1–N3 group ($P < 0.05$)

strongly suggest that miR-30b down-regulates the expression of Cthrc1 by binding to its 3'UTR.

Expression of Cthrc1 restores miR-30b anti-invasion function

We next performed western blotting and trans-well assays to explore whether the effect of miR-30b can be partially restored by Cthrc1 re-expression, which also further confirm that Cthrc1 is a direct target of miR-30b. The Cthrc1 expression in A549 and Calu-3 cells were lower after transfection with miR-30b mimics, and was higher after transfection with vector containing Cthrc1 lacking the 3'UTR (pcDNA3.1-Cthrc1) into two cells. Co-transfection of miR-30b mimics and pcDNA3.1-Cthrc1 led to increased expression of Cthrc1, and abrogated the Cthrc1 expression-reducing effect of miR-30b mimics (Fig. 5a, b). For trans-well assays, the mean number of cells penetrating the trans-well membrane and matrigel decreased after transfection with miR-30b mimics, but increased after transfection with pcDNA3.1-Cthrc1 and co-transfection with pcDNA3.1-Cthrc1 and

miR-30b mimics, abrogating the effect of miR-30b mimics (Fig. 5c, d). These results further suggest that Cthrc1 is a major target of miR-30b, and expression of Cthrc1 restores miR-30b anti-invasion function.

Discussion

Lung cancer accounts for the foremost cause of malignancy-associated death worldwide, and metastasis is one of the major problems. To metastasize, a cancer cell must acquire abilities such as the capacity to colonize new tissue and evade immune surveillance, which must involve a broad spectrum of mechanisms. Gene expression profiling experiments have uncovered many genes potentially implicated in cancer invasion and metastasis [25–28]. Matrix metalloproteinases (MMPs), a family of zinc-ion dependent endopeptidases comprising more than 21 subtypes, have been widely accepted to play an important role on cancer invasion or metastasis [29–32]. In kinds of cancers, a wide spectrum of target genes are simultaneously regulated by multiple miRNAs, which leads to altered expression of invasion or metastasis-associated

Table 1 miR-30b and Cthrc1 mRNA expression levels were associated with clinicopathological features of NSCLC patients

Clinicopathological factor	n	miR-30b($2^{-\Delta\Delta Ct}$)		Cthrc1 mRNA($2^{-\Delta\Delta Ct}$)	
		Median \pm SD	P	Media \pm SD	P
Gender					
Male	38	0.2847 \pm 0.1138	0.720	2.2714 \pm 0.3568	0.707
Female	24	0.2960 \pm 0.1307		2.2371 \pm 0.3359	
Age (years)					
≥ 60	35	0.3081 \pm 0.1324	0.156	2.222 \pm 0.3971	0.345
<60	27	0.2644 \pm 0.0979		2.305 \pm 0.2672	
Histology					
SCC	21	0.3033 \pm 0.0992	0.508	2.2548 \pm 0.2960	0.957
AC	41	0.2818 \pm 0.1295		2.2599 \pm 0.3732	
Differentiation					
Well	21	0.3455 \pm 0.1533	0.007*	2.1035 \pm 0.4324	0.011*
Moderate & Poor	41	0.2602 \pm 0.0870		2.3374 \pm 0.2656	
TNM					
I	25	0.3540 \pm 0.1327	0.000*	2.1010 \pm 0.3440	0.005*
II	23	0.2663 \pm 0.0927		2.3126 \pm 0.2796	
III	14	0.2107 \pm 0.0677		2.4494 \pm 0.3470	
Lymphnode metastasis					
N0	47	0.3129 \pm 0.1234	0.005*	2.1952 \pm 0.3290	0.010*
N1–N3	15	0.2147 \pm 0.0670		2.4555 \pm 0.3352	

SCC squamous cell carcinoma, AC adenocarcinoma


* Indicated statistical significance ($P < 0.05$)

genes and influences the metastatic potential of many cancers [33–35]. Learning more about the cellular and molecular basis of miRNA-target gene axis in cancers will help us to understand how cancer cells disseminate and lead to new treatment strategies.

Accumulating evidences have suggested that alterations in miRNAs expression might prove crucial in cancer metastasis. In NSCLC, miR-29b was found down-regulated in high-metastatic NSCLC cells and low-expression of miR-29b in primary NSCLC tissue and correlated with lymph node metastasis [36]. In vitro and in vivo experiments, miR-425-5p contributes to invasion and metastasis of human gastric cancer [37]. In melanoma cells, miR-203 was revealed to regulate melanoma invasive and proliferative abilities in part by targeting BMI1. Our research focused on miR-30b, which has been demonstrated that enhanced the invasive capacity of melanoma cells in vitro and increased their metastatic potential in vivo [38]. MiR-30 was described as a “hub” for miRNA oncogenesis signal network in solid tumors [39]. Its up- or down- modulation has profound impacts on tumorigenesis. In our study, we found that altered miR-30b expression was associated with the occurrence of the differentiation status, TNM stage and lymph node metastases in NSCLC patients, which may be a hint for

miR-30b acting as a potential tumor-suppressor contributing to the progression and metastasis of NSCLC. Nevertheless, it still needs to explore the relevant mechanism of miR-30b in NSCLC invasion and metastasis.

Naturally, many other genes as MMP family [40] and Cthrc1 [24] have been demonstrated to associate with NSCLC invasion and metastasis during the ongoing researches of NSCLC. Based on bioinformatics analysis, we detected the Cthrc1 mRNA expression and found elevated expression of Cthrc1 was also associated with the occurrence of the differentiation status, TNM stage and lymph node metastases in NSCLC patients, and Pearson correlation analysis indicated that the expression of miR-30b and Cthrc1 mRNA were inversely correlated. Furthermore, we up-regulated the expression of miR-30b in NSCLC cell lines, and found up-regulation of miR-30b restricted cell migration and invasion. Western blotting array was used to analyze the expression of invasion-related proteins and the results showed that Cthrc1, MMP-9 and MMP-2 were declined but TIMP-1 was increased following transfection with miR-30b in A549 and Calu-3 cells, which is a hint that miR-30b plays an important role in cell migration and invasion of NSCLC. Owing to the role of miRNA was realized by targeting the gene expression, the related mechanism need to be



further analyzed. Bioinformatics analysis revealed that one target of miR-30b was Cthrc1. The 3'UTR region of Cthrc1 was amplified from human genomic DNA and inserted into the pmirGLO vector to construct a luciferase reporter plasmid. After transfection into A549 and Calu-3 cells, western blotting and luciferase reporter assays were performed and the results demonstrated that miR-30b regulated Cthrc1 by directly binding to its 3'UTR. Moreover, western blotting and trans-well assays further suggest that Cthrc1 is a major target of miR-30b, and expression of Cthrc1 restores miR-30b anti-invasion function.

Conclusions

MiR-30b was down-regulated and Cthrc1 up-regulated in NSCLC tissues. Both of them were related to tumor differentiation, TNM stage and lymph node metastases. We also provided evidence demonstrating miR-30b affected NSCLC cells invasion and migration by regulating Cthrc1 expression. In the future, the miR-30b-Cthrc1 pathway could be exploited in a therapeutic approach for the treatment of NSCLC.

Methods

Patients and tissue specimens

Paired tumorous and adjacent normal tissues (≥ 3 cm away from tumor) were obtained from 63 NSCLC patients. All specimens were clinically and histologically diagnosed at the First Affiliated Hospital of Zhengzhou University between 2012 and 2014. The tumorous and adjacent normal tissues were snap-frozen in liquid nitrogen immediately after resection and stored at -80°C until RNA extraction. This study was approved by the Ethics Committee of Zhengzhou University and written consent was obtained from all patients.

Cell culture

Normal human bronchial epithelial cells (NHBE) and two human lung cancer cell lines (A549 and Calu-3) were used in this study (American Type Culture Collection, Manassas, VA, USA). NHBE, A549 and Calu-3 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Gibco, CA, USA) containing 10 % fetal bovine serum (FBS; Gibco), 100 U/mL penicillin and 100 $\mu\text{g/mL}$ streptomycin at 37°C with a humidified 5 % CO_2 atmosphere.






Fig. 3 MiR-30b inhibits NSCLC cells migration and invasion. **a** After transfection of miR-30b mimics or Scramble, qRT-PCR results showed miR-30b expression was significantly increased in miR-30b group compared with NHBE group, Scramble and Blank groups ($P < 0.05$). **b** Wound healing assays were used to assess the migration ability of A549 and Calu-3 cells after transfection. miR-30b group showed a lower cell density at 24 h post-wounding compared with both Scramble and Blank groups ($P < 0.05$). **c** Transwell migration assays were used to assess the migration ability of A549 and Calu-3 cells after transfection. The numbers of A549 and Calu-3 cells in the miR-30b group passing through membrane were significantly lower compared with those from the Scramble and Blank groups ($P < 0.05$). **d** Transwell invasion assays were used to assess the invasion ability of A549 and Calu-3 cells after transfection. The numbers of A549 and Calu-3 cells in the miR-30b group passing through the membrane and matrigel were significantly lower compared with those from the Scramble and Blank groups ($P < 0.05$). **e, f** Western blotting was used to analyze the expression of Cthrc1 and some other invasion-related proteins such as Cthrc1, TIMP-1, MMP-2 and MMP-9 in A549 and Calu-3 cells. The results showed that Cthrc1, MMP-2 and MMP-9 were declined but TIMP-1 was increased following transfection with miR-30b in A549 and Calu-3 cells ($P < 0.05$). miR-30b cells transfected with miR-30b mimics; Scramble cells transfected with scrambled miR-30b negative control; Blank cells with non-transfected

RNA extraction and quantitative real-time PCR

Quantitative real-time PCR (qRT-PCR) arrays were used to detect the relative levels of miR-30b and Cthrc1 mRNA in 63 paired tumorous and adjacent normal tissues. Total

RNA was extracted from those frozen tissue samples containing >80 % NSCLC cells. An RNA Extraction Kit (Qiagen) was used to extract total RNA according to the manufacturer's instructions and RNA quality was



confirmed using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). RNA purity was determined by an OD_{260/280} value of at least 1.8. For miR-30b expression, cDNA was obtained using the miScript Reverse Transcription Kit (Qiagen) with specific miRNA primers (Applied Biosystems). MiR-30b expression was detected using the TaqMan human microRNA assay kit (Qiagen). U6 snRNA was used as an endogenous control to normalize the data. For Cthrc1 mRNA expression, RNA was reverse-transcribed with random primers using an ABI® Reverse Transcription Kit (Applied Biosystems) and qRT-PCR were performed

using ABI Power SYBR® Green I PCR Master Mix (Applied Biosystems) on the ABI 7500 Fast (Applied Biosystems) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. Data were analyzed using ABI Prism7500 SDS Software (Applied Biosystems, USA). All protocols were performed according to the manufacturers' instructions. The comparative cycle threshold (CT) ($2^{-\Delta\Delta CT}$) method was used to calculate the relative expression of miR-30b and Cthrc1 mRNA.

Western blotting

Total protein from each group was extracted and the protein concentration was measured using the Bradford DC protein assay (Bio-Rad, Hercules, CA, USA). 25 µg protein from each sample was separated using SDS-polyacrylamide gel electrophoresis (10 %) and blotted onto polyvinylidene difluoride (PVDF) filter membranes (Whatman). The membranes were blocked in 5 % skim milk for 1 h, washed four times with Tris-buffered saline containing Tween 20 (TBST) at room temperature and then incubated overnight at 4 °C with diluted primary antibodies (rabbit anti-human Cthrc1/TIMP-1/MMP-2/MMP-9 antibody, 1:500, Santa Cruz). Following extensive washing with TBST, membranes were incubated with secondary antibodies at room temperature for 1 h (goat anti-rabbit IgG, 1:1000, Santa Cruz). After four 15 min washes with TBST at room temperature, immunoreactivity was visualized by enhanced chemiluminescence. GAPDH expression (Santa Cruz Biotechnology) served as an endogenous reference.

Cell transfection

For transfection, A549 and Calu-3 cells were seeded into 6-well plates at a density of 5×10^4 cells/well. Transient transfection was performed at approximately 80 % confluence using Lipofectamine™2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. 50 nM GMR-miRTM was mixed with a miR-30b mimic or scrambled miR-30b negative control (Shanghai GenePharma) in 1 µl of Lipofectamine reagent. After 24 h, qRT-PCR was used to evaluate transfection efficiencies. According to the requirements of the different experiments, A549 and Calu-3 cells were separated into three respective groups; Blank: untransfected cells, Scrambled: cells transfected with scrambled miR-30b negative control, and miR-30b: cells transfected with miR-30b mimics.

Wound healing assay

Cell migration was analyzed using the wound healing assay. At 90 % density in 6-well plates, a sterile 200 µL pipette tip was used to scratch a straight line through the A549 and Calu 3 cell layers and the culture medium was

changed. Cells were photographed 24 h after scratching. Assays were repeated three times for each clone.

Trans-well assay

For cell invasion assay, trans-well filters (Costar) were coated with matrigel (3.9 µg/µl, 60–80 µl) on the upper surface of a polycarbonic membrane (6.5 mm diameter, 8 µm pore size). After 24 h post-transfection and then 6 h serum starvation, A549 and Calu-3 cells (2×10^5) were resuspended in 200 µl of serum-free medium in the upper chambers, and while 500 µl media containing 10 % FBS (as a chemoattractant) was added to the bottom chamber. After incubating for 8 h at 37 °C in a humidified incubator with 5 % CO₂, cells in the upper chamber were carefully removed with a cotton swab. Cells that had migrated to the basal side of the membrane were fixed with methanol, stained with hematoxylin, mounted and dried at 80 °C for 30 min. We randomly selected three visual fields and counted and recorded the number of cells invading the matrigel with an inverted microscope at 200× magnification. Each test was performed in triplicate. With the similar principle and approach, we used trans-well filters (Costar) with uncoated matrigel on the upper surface of a polycarbonic membrane (6.5 mm diameter, 8 µm pore size) for cell migration assay.

Vector construction and the dual-luciferase reporter assay

The 3'UTR region of Cthrc1 was amplified from human genomic DNA and inserted into the pmirGLO vector (Promega, Madison, WI, USA) with XhoI and SalI at the 3' end of the luciferase gene to construct the luciferase reporter plasmids pmirGLO-Cthrc1-Wt and pmirGLO-Cthrc1-Wt. Site-directed mutagenesis of the miR-30b target site in the Cthrc1 3'UTR was performed using a QuikChange Site-Directed Mutagenesis kit (Promega) and pmirGLO-Cthrc1-Wt as the template. For the luciferase reporter assay, A549 and Calu-3 cells were seeded into 96-well plates and transfected with 50 nM of miR-30b mimic or Scrambled and 200 ng of luciferase reporter plasmid (pmirGLO-Cthrc1-Wt/pmirGLO-Cthrc1-Mut) using Lipofectamine™2000 (Invitrogen). 48 h after transfection, cells were harvested and luciferase activity was measured with a Dual-Luciferase assay kit (Promega) according to the manufacturer's instructions.

Statistical analysis

All analyses were performed with SPSS 17.0 software. Normal distribution was confirmed by the normal distribution test and data were expressed as mean ± standard deviation. Significance between groups was analyzed using the student's t test and one-way analysis of variance (ANOVA). Pearson correlation analysis was used to

analyze correlation between different variable elements. $P < 0.05$ was considered statistically significant.

Abbreviations

NSCLC: non-small cell lung cancer; miRNAs: microRNAs; Cthrc1: collagen triple helix repeat containing 1; qRT-PCR: quantitative reverse transcription polymerase chain reaction; MMPs: matrix metalloproteinases; MMP-9: matrix metalloproteinase-9; MMP-2: matrix metalloproteinase-2; TIMP-1: metalloproteinase inhibitor-1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; NHBE: normal human bronchial epithelial cell; DMEM: dulbecco's modified eagle medium; FBS: fetal bovine serum; CT: cycle threshold; PVDF: polyvinylidene difluoride; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBST: tris-buffered saline containing tween 20; TNM: tumor node metastasis; ANOVA: one-way analysis of variance.

Authors' contributions

GJZ and GQZ, and SSC: conceived of the study, and participated in its design and coordination and helped to draft the manuscript. SSC, PL, RY, RRC and FRZ: collected the samples. SSC, YYW, XNC, QQS, WQZ and YWD: carried out part of experiments. YYW, XNC, GJZ and GQZ performed the statistical analysis. All authors read and approved the final manuscript.

Author details

¹ Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. ² Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Acknowledgements

The authors are grateful to all staff at the study centre who contributed to this study. This study was supported by the Ministry of Health of Henan (201401005).

Compliance with ethical guidelines

Competing interests

The authors declare that they have no competing interests.

Received: 8 June 2015 Accepted: 1 September 2015

Published online: 17 September 2015

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65:5–29.
- Nguyen KS, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. *World J Clin Oncol*. 2014;5:576–87.
- Habib S, Delourme J, Dhalluin X, Petyt G, Tacelli N, Scherpereel A, et al. Bevacizumab and weekly paclitaxel for non-squamous non-small cell lung cancer patients: a retrospective study. *Lung Cancer*. 2013;80:197–202.
- Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. *Onkologie*. 2013;36:510–8.
- Sgambato A, Casaluze F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? *J Thorac Dis*. 2014;6:578–80.
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*. 2008;26:3543–51.
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Eng J Med*. 2002;346:92–8.
- Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res*. 2006;34:D140–4.
- Cheng C, Bhardwaj N, Gerstein M. The relationship between the evolution of microRNA targets and the length of their UTRs. *BMC Genom*. 2009;10:431.
- Cheng Q, Yi B, Wang A, Jiang X. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. *Onco Targets Ther*. 2013;6:1675–84.
- Li J, Li P, Chen T, Gao G, Chen X, Du Y, et al. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. *Tumour Biol*. 2015;36:685–92.
- Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. *Mol Cell Biochem*. 2013;372:35–45.
- Chu H, Chen X, Wang H, Du Y, Wang Y, Zang W, et al. MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. *Tumour Biol*. 2014;35:3487–94.
- Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. *Oncogene*. 2014;33:1181–9.
- Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, et al. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by down-regulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. *Oncogene*. 2015;34:413–23.
- Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. *Oncogene*. 2010;29:4194–204.
- Feber A, Wilson GA, Zhang L, Presneau N, Idowu B, Down TA, et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. *Genome Res*. 2011;21:515–24.
- Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. *Oncogene*. 2012;31:4001–8.
- Zhong K, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. *BMC Cancer*. 2014;14:703.
- Tameda M, Sugimoto K, Shiraki K, Yamamoto N, Okamoto R, Usui M, et al. Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility. *Int J Oncol*. 2014;45:541–8.
- Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. *Clin Cancer Res*. 2006;12:3716–22.
- Ip W, Wellman-Labadie O, Tang L, Su M, Yu R, Dutz J, et al. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. *J Cutan Med Surg*. 2011;15:103–10.
- Wang P, Wang YC, Chen XY, Shen ZY, Cao H, Zhang YJ, et al. CTHRC1 is upregulated by promoter demethylation and transforming growth factor- β 1 and may be associated with metastasis in human gastric cancer. *Cancer Sci*. 2012;103:1327–33.
- Liu X, Liu B, Cui Y, Wang F, Sun H, Lv F. Collagen triple helix repeat containing 1 (Cthrc1) is an independently prognostic biomarker of non-small cell lung cancers with cigarette smoke. *Tumour Biol*. 2014;35:11677–83.
- Chen W, Cao G, Yuan X, Zhang X, Zhang Q, Zhu Y, et al. Notch-1 knock-down suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells. *J Transl Med*. 2015;13:167.
- Fang Y, Liang X, Jiang W, Li J, Xu J, Cai X. Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin. *PLoS One*. 2015;10:e0126875.
- Zhao S, Li H, Wang Q, Su C, Wang G, Song H, et al. The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α 2M. *BMC Cancer*. 2015;15:389.
- Li D, Mei H, Pu J, Xiang X, Zhao X, Qu H, et al. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2. *Mol Cancer*. 2015;14:47.
- Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. *Front Cell Dev Biol*. 2015;3:4.
- Jacob A, Jing J, Lee J, Schedin P, Gilbert SM, Peden AA, et al. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. *J Cell Sci*. 2013;126:4647–58.

31. Stellas D, El Hamidieh A, Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. *BMC Cell Biol.* 2010;11:51.
32. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. *J Natl Cancer Inst.* 1997;89:1260–70.
33. Liang L, Li X, Zhang X, Lv Z, He G, Zhao W, et al. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. *Gastroenterology.* 2013;144(624):635.e4.
34. Zhong M, Bian Z, Wu Z. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. *Cell Physiol Biochem.* 2013;31:209–18.
35. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. *Hepatology.* 2012;55:1852–62.
36. Wang HY, Tu YS, Long J, Zhang HQ, Qi CL, Xie XB, et al. SRF-miR-29b-MMP2 axis inhibits NSCLC invasion and metastasis. *Int J Oncol.* 2015;47:641–9.
37. Zhang Z, Li Y, Fan L, Zhao Q, Tan B, Li Z, et al. microRNA-425-5p is upregulated in human gastric cancer and contributes to invasion and metastasis in vitro and in vivo. *Exp Ther Med.* 2015;9:1617–22.
38. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. *Cancer Cell.* 2011;20:104–18.
39. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. *Genome Res.* 2010;20:589–99.
40. Yu G, Herazo-Maya JD, Nukui T, Romkes M, Parwani A, Juan-Guardela BM, et al. Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. *Am J Respir Crit Care Med.* 2014;190:780–90.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

